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Previewsnucleation sites for de novo methylation
(Athanasiadou et al., 2010).
The results bySchu¨beler andcolleagues
provide important insights into how the
underlying genome sequence guides cell-
type-specific DNA methylation patterns.
However, establishment of histone meth-
ylation patterns is also regulated by the
genome sequence and TF binding and
activity, making it difficult to draw clear-
cut conclusions about specific casual rela-
tionships. DNA methylation patterns and
H3K4 methylation patterns are strongly
anticorrelated (Meissner et al., 2008;
Weber et al., 2007). Moreover, these two
epigenetic modifications are regulated by
inverse requirements for unmethylated
cytosinesbyCfp1within theSetd1methyl-
transferase complex (Deaton and Bird,
2011) and for unmodified H3K4 residues
in nucleosomes during Dnmt3l-mediated390 Cell Stem Cell 9, November 4, 2011 ª20recruitment of Dnmt3a (Ooi et al., 2007).
Chromatin regulators generally appear to
lack sequence-directed target specificity,
and as a consequence are also likely re-
cruited to specific loci by the genomic
context and DNA binding factors. Inte-
grating the relationship between cis-regu-
latory elements and DNA methylation
described by Lienert et al. into the larger
context of other epigenetic modifiers
should provide new and exciting rules for
how these signatures dictate cell-type
specific regulation.REFERENCES
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Understanding how individual hematopoietic stem cells contribute to blood formation requires analysis at the
single-cell level. Recently in Nature Biotechnology, Lu et al. (2011) tagged HSCs with unique molecular barc-
odes and used high-throughput sequencing to track their progeny after transplantation.The stem cell hierarchy of high-turnover
tissues of the adult is rather complex.
Blood formation, one of the most active
and certainly the best characterized stem
cell system in the adult, includes multiple
layers of stem and progenitor cells. Our
knowledge on the in vivo biology of dif-
ferent classes within the hematopoietic
stem cell (HSC) tree has largely been
gained from FACS and subsequent trans-
plantation into syngeneic recipient mice
(Dykstra et al., 2007; Weissman and Shi-
zuru, 2008). True quantification of how
specific subpopulations contribute to
blood formation has, however, proven
difficult. Suitable phenotypic markers arenot available for all functionally defined
stem and progenitor cell types. Associa-
tion of a marker profile to a cell’s function-
ality may not be inherently fixed under all
in vivo conditions, and even less so after
extensive in vitro manipulation or intro-
duction of genetic modifications. Limiting
dilution analysis, the most commonly
used assay to quantify HSC content,
allows the quantification of stem cells
without restriction to a certain phenotype
but is biased toward larger and more
frequent stem cell clones. In vivo ap-
proaches to detect functional HSC output
can also not account for the fact that mul-
tiple stem or progenitor cells make simul-taneous contributions to the observed
blood cell output. In a recent article pub-
lished in Nature Biotechnology, Irving
Weissman and colleagues use a new
methodology to smartly track individual
HSC’ contributions to overall blood forma-
tion (Lu et al., 2011). By introducing a
distinguishable 27 bp variable DNA bar-
code sequence within a lentiviral vector
into individual stem and progenitor cells
before transplantation, posttransplanta-
tion hematopoiesis in their animals carries
a clonal barcode marker in each cell’s
blood cell output. This refinement of a
novel technique allows them to catch
a first glimpse of the clonal repertoire
Figure 1. Clonal Tracking of Virally Marked Stem Cell Clones
The progeny of individual stem cell clones that were marked by integrating viral vectors can be tracked after transplantation using two strategies. Barcodes intro-
duced into the marking vector can be efficiently amplified genome-wide. This strategy allows an unbiased quantification of clonal contribution (left). On the other
hand, the exact genomic location of vector integration enables deciphering the influence of vector integration on the stem cell clones’ biology (right). LTR, long
terminal repeat; R, restriction enzyme motif; red arrows, PCR primers; colored lines, PCR amplicons.
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Previewsthrough visualizing the distribution of
the introduced barcodes in posttrans-
plant hematopoiesis by high-throughput
sequencing.
Earlier, in a series of sometimes breath-
takingly surprising, sometimes unwel-
come discoveries, therapeutic clinical
trials in the translational research field of
gene therapy have brought the hemato-
poiesis field a lot closer to the holy grail
of visualizing the full clonal repertoire of
transduced hematopoietic transplants in
animal models, and even in humans. As
a mostly unwanted side effect, the semi-
random integration of retroviral and lenti-
viral vector systems in gene therapycreates a different genetic location of the
vector provirus in each transduced pro-
genitor cell. Herein lies both the greatest
strength and weakness of this earlier
data (Nolta and Jordan, 2001). The num-
ber of such inserts and the copy number
present provide astonishingly precise
mappings of the repertoire of transduced
cells and their progeny. A sophisticated
methodology has been developed that
can read out the sequence of each fusion
sequence between the proviral vector
insert and its surrounding genomic loca-
tion (Gabriel et al., 2009, Schmidt et al.,
2007). The weakness of using retrovirus
insertional flanks as a marker for clonalCell Stem Cell 9,contribution lies in the fact that the in-
sertion is a genetic mutation that is not
biologically inert. Detailed analyses by us
and a number of other investigators have
clearly confirmed in vectors what mature
retrovirologists knew all along from their
viruses: retrovirus insertion can change
clonal contribution to hematopoiesis in a
big way, from slight changes in clonal
contribution to overt clonal dominance
and even leukemia (Bushman, 2003; Dei-
chmann et al., 2007; Hacein-Bey-Abina
et al., 2003; Kustikova et al., 2005; Stein
et al., 2010). This effect is reduced sub-
stantially if vectors are derived from lenti-
viruses such as the human AIDS virus HIVNovember 4, 2011 ª2011 Elsevier Inc. 391
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Previewsand the viral promoter/enhancer elements
are inactivated, but it cannot be totally
excluded.
Considering all this, there must be
a more elegant solution for tagging blood,
Weisman and colleagues may have rea-
soned. What if the marker itself had a
random tagging element, similar to a
barcode? Blood cell clones could then
be compared independent of where the
vector happens to sit in each clone. Their
approach of DNA barcoding blood
formation presented in this paper
profoundly extends our capability to
monitor the clonal activity of transduced
cells in vivo (Figure 1). DNA barcoding
with random sequence tags has partic-
ular strengths. It allows accessing and
quantifying inserted vectors genome-
wide in a variety of benign and malignant
tissues. Flanking the barcode sequence
with two primer sequences uncouples
its PCR amplification from the variability
of an integration locus. Amplicons are of
identical length for each marked clone,
eliminating amplification size bias. Read
counts generated by high-throughput
sequencing of these amplicons are there-
fore likely to very closely reflect the actual
quantitative representation of each
marked clone. This methodology allowed
Lu et al. to discover an inhomogeneous
participation and lineage bias of indi-
vidual HSC clones in posttransplant
hematopoiesis (Lu et al., 2011). Because392 Cell Stem Cell 9, November 4, 2011 ª20multiple stem cell clones could be
tracked simultaneously, genetic marking
dramatically reduced the number of
mice required. Barcoding of adult stem
cells in other organs or of tumor-initiating
cells holds the promise to substantially
broaden our understanding of the cellular
organization of normal and malignant
tissues.
On a cautionary note, barcoding alone
cannot distinguish whether the lentiviral
vector integration has affected the target
cells’ biology. Sequencing of the genomic
integration flanks will still be required to
discriminate between the natural fate of
a transduced cell and a biological modifi-
cation of a clone’s activity that resulted
from the insertion of the vector into a
relevant site of the genome. Barcoding
in clinical gene therapy may still be some
distance further down the road. The
number of different barcodes is limited
and surely not yet sufficient to transduce
the currently transplanted number of at
least 107 hematopoietic cells in individual
patients. In addition, preclinical toxicity
testing of a large number of DNA se-
quence variants might be difficult to
achieve. However, for our ability to dis-
cover and understand stem cell systems,
barcode-based clone size quantification
will open a new dimension in deciphering
the clonal real-time contribution of indi-
vidual stem cell clones: stem cells you
can count (on).11 Elsevier Inc.REFERENCES
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